SURMOUNT-OSA tirzepatide trials
AHI treatment differences versus placebo were about -20.0 events/hour in trial 1 and -23.8 events/hour in trial 2; secondary sleep/cardiometabolic measures also improved.
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Adults with moderate-to-severe OSA and obesity, with and without PAP use
n=469
AHI treatment differences versus placebo were about -20.0 events/hour in trial 1 and -23.8 events/hour in trial 2; secondary sleep/cardiometabolic measures also improved.
Population had obesity and moderate-to-severe OSA; results should not be generalized to non-obese sleep disorders.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
AHI treatment differences versus placebo were about -20.0 events/hour in trial 1 and -23.8 events/hour in trial 2; secondary sleep/cardiometabolic measures also improved.